Melanoma (stage III or IV) - ipilimumab: review decision - April 2015
The Institute was proposing that the guidance should be incorporated into the ongoing clinical guideline for melanoma.
Stakeholder responses (available in Appendix A) were in favour of this proposal, but after further consideration the Institute’s Guidance Executive has decided that this may not be the most appropriate course of action.
The related appraisal TA319; Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma is scheduled to be considered for review in June 2017 and it is possible that evidence relating to this topic might have implications for TA268. As a result, it would be beneficial to consider TA268 and TA319 for review together.
Consequently, the Institute’s Guidance Executive has decided that TA268 should move to the static list of technology appraisals until it is considered for review alongside TA319 in June 2017. Rather than incorporating the recommendations from TA268, the forthcoming guideline will cross-refer to the appraisal instead.
This page was last updated: 24 April 2015